Weight Management
Tirzepatide
A dual GIP and GLP-1 receptor agonist that acts on two gut hormone pathways at once.
What it's researched for
- Studied in research settings for appetite regulation, blood sugar control and body weight.
- Dual action has made it a major focus of recent metabolic research.
- Researched with once-weekly protocols.
READ THE RESEARCH ↗
SURMOUNT-1 trial (New England Journal of Medicine): tirzepatide once weekly for the treatment of obesity — up to 20.9% body-weight reduction.
SIZE
£109.99
99% PURITY GUARANTEEFREE DELIVERY For laboratory research use only. Not for human consumption. Not intended to diagnose, treat, cure or prevent any disease.